**WHAT IS CLAIMED IS:**

1. A compound for use in treating gout in a patient on concomitant thiazide diuretics, wherein the patient is not adequately responding to a non-lesinurad urate lowering therapy, wherein the compound is lesinurad.
2. The compound for use of claim **1**, wherein a dose of lesinurad is 200 mg.
3. The compound for use of claim **1**, wherein a dose of lesinurad is 400 mg.
4. The compound for use of claim **1**, wherein the non-lesinurad urate lowering therapy is allopurinol.
5. A compound for use in reducing the incidences of or likelihood of or reversing hyperuricemia or gout in a patient receiving thiazide treatment, wherein the compound is an OAT4 inhibitor.
6. The compound for use of claim 5, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.
7. The compound for use of claim 5, wherein the thiazide treatment is treatment with hydrochlorothiazide, bendroflumethiazide, benzothiadiazine, hydroflumethiazide, chlorothiazide, methyclothiazide, polythiazide, chlorthalidone, metolazone, indapamide, bumetanide, ethacrynic acid, furosemide or torsemide.
8. A compound for use in reducing or reversing hyperuricemia or gout in a patient receiving hydrochlorothiazide, wherein the compound is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.
9. A compound for use in reducing serum uric acid levels in a patient suffering from hypertension, wherein the compound is an OAT-4 inhibitor,
   wherein the patient is receiving a thiazide diuretic, and
   wherein administration of the thiazide diuretic results in elevated serum uric acid levels.
10. The compound for use of claim 9, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.
11. A composition comprising:
    (i) a thiazide diuretic;
    (ii) an OAT-4 inhibitor; and
    (iii) a pharmaceutically acceptable excipient or carrier.

12. A composition comprising:

(i) a thiazide diuretic;

(ii) 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof; and

(iii) a pharmaceutically acceptable excipient or carrier.

13. A composition comprising:

(i) hydrochlorothiazide;

(ii) 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof; and

(iii) a pharmaceutically acceptable excipient or carrier.

**WHAT IS CLAIMED IS:**

1. Use of lesinurad in combination with allopurinol in the manufacture of a medicament for treating gout in a patient on concomitant thiazide diuretics.
2. The use of claim 1, wherein a dose of lesinurad is 200 mg.
3. The use of claim 1, wherein a dose of lesinurad is 400 mg.
4. Use of an OAT4 inhibitor in the manufacture of a medicament for reducing the incidences of or likelihood of or reversing hyperuricemia or gout in a patient receiving thiazide treatment.
5. The use of claim 4, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio )acetic acid or a pharmaceutically acceptable salt thereof.
6. The use of claim 4, wherein the thiazide treatment is treatment with hydrochlorothiazide, bendroflumethiazide, benzothiadiazine, hydroflumethiazide, chlorothiazide, methyclothiazide, polythiazide, chlorthalidone, metolazone, indapamide, bumetanide, ethacrynic acid, furosemide or torsemide.
7. Use of 2-( 5-bromo-4-( 4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio )acetic acid or a pharmaceutically acceptable salt thereof in combination with allopurinol in the manufacture of a medicament for reducing or reversing hyperuricemia or gout in a patient receiving hydrochlorothiazide.
8. Use of an OAT4 inhibitor in combination with allopurinol in the manufacture of a medicament for reducing serum uric acid levels in a patient suffering from hypertension, wherein the patient is receiving a thiazide diuretic, and wherein administration of the thiazide diuretic results in elevated serum uric acid levels.
9. The use of claim 8, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-l,2,4-triazol-3-ylthio )acetic acid or a pharmaceutically acceptable salt thereof.
10. A composition comprising:
    i. a thiazide diuretic;
    ii. an OAT4 inhibitor;
    iii. allopurinol; and
    iv. a pharmaceutically acceptable excipient or carrier.
11. A composition comprising:

i. a thiazide diuretic;

ii. 2-(5-bromo-4-( 4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio )acetic acid or a pharmaceutically acceptable salt thereof;

iii. allopurinol; and

iv. a pharmaceutically acceptable excipient or carrier.

12. A composition comprising:

i. hydrochlorothiazide;

ii. 2-(5-bromo-4-( 4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio )acetic acid or a pharmaceutically acceptable salt thereof;

iii. allopurinol; and

iv. a pharmaceutically acceptable excipient or carrier.